# Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR)

> **NCT02921139** · NA · UNKNOWN · sponsor: **Dalin Tzu Chi General Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Hepatocellular Carcinoma(HCC)

## Interventions

- **RADIATION:** Stereotactic ablative radiotherapy (SABR)
- **PROCEDURE:** Re-Transcatheter arterial chemoembolization (re-TACE)

## Key facts

- **NCT ID:** NCT02921139
- **Lead sponsor:** Dalin Tzu Chi General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2022-11
- **Final completion:** 2022-11
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2021-08-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02921139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02921139, "Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR)". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT02921139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*